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a  b  s  t  r  a  c  t
Langerhans  cells  (LC),  the  skin  epidermal  contingent  of  dendritic  cells  (DC),  possess  an  exceptional  life
cycle and  developmental  origin.  LC,  like all mature  blood  cells,  develop  from  haematopoietic  stem  cells
(HSC)  through  successive  steps  of lineage  commitment  and  differentiation.  However,  LC development
is  different  to  that  of other  DC  subsets  and  not  yet  fully  understood.  Haematopoietic  cell fate  decisions
are  instructed  by speciﬁc  growth  factors  and  cytokines  produced  in  specialized  microenvironments  or
niches. Upon  ligand  binding  the  cognate  surface  receptors  on  HSC  and  further  restricted  progenitor  cells
regulate the  signalling  pathways  that  eventually  leads  to  the  execution  of lineage-determining  genetic
programs.  In  this  review  we  focus  on a speciﬁc  set  of  surface  receptor  kinases  that  have  been  identiﬁed
as  critical  regulators  of  LC development  using  genetically  modiﬁed  mice.  Recent  studies suggest  for  some
of these  kinases  to  impact  on  LC/LC  progenitor  interaction  with  the  local  niche  by regulating  adhesion
and/or  migration.  During  embryonic  development,  in  wound  healing  and  aberrantly  in tumour  invasion
the  same  kinase  receptors  control  a genetic  program  known  as epithelial-to-mesenchymal-transition
(EMT).  We  will  discuss  how  EMT  and  its reverse  program  of  mesenchymal-to-epithelial-transition  (MET)
can  serve  as  universal  concepts  operating  also  in  LC  development.© 2014  The  Authors.  Published  by Elsevier  Ltd.  This  is an  open  access  article  under  the  CC  BY-NC-ND
license  (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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. Introduction
Langerhans cells (LC) represent the dendritic cell (DC) subset in
kin epidermis and other stratiﬁed epithelia. Due to their special-
zed location LC constitute the ﬁrst immune barrier for invading
athogens but have also been implicated in tolerance induction
1–4]. Two further major DC subpopulations are plasmacytoid DC
pDC) and tissue/interstitial/dermal DCs (dDC) (frequently referred
o as “conventional” or “classical” DC, cDC). All DC in peripheral
rgans act as sentinels of the immune surveillance system and are
herefore particularly abundant in tissue that serves as an inter-
ace to the environment, such as skin, airways, and intestine. pDC
nd cDC represent also the two major lymphoid tissue-resident DC
opulations in steady state [5,6].
Notably, the functional and phenotypic diversity of DC sub-
ets was not instrumental to delineate DC lineage speciﬁcity.
or example, it was found that all cDC and pDC can originate
rom both early clonal common lymphoid progenitors (CLP) and
yeloid committed progenitors (Fig. 1) [5,7]. Additionally, cDC
nd pDC share a common developmental origin that became
pparent with the identiﬁcation of common DC progenitors: a
lt3+ Csf1R+ CX3CR1+ common macrophage/DC progenitor (MDP)
8–11] and a Flt3+ c-kitint Csf1R+ common DC progenitor (CDP)
11–13]. MDP  give rise to macrophages and DC but not gra-
ulocytes. MDP  are the direct progenitors of CDP, which are
C-restricted and do not generate other cell types. However, these
tudies did not address the potential of MDP/CDP to differentiate
nto LC.
While much is known about LC activation and trafﬁcking
owards the skin-draining lymph nodes (LNs), only recent stud-
es addressed questions on the developmental origin of LCs and
he molecular mechanisms involved [2,4,6,14–16]. It becomes
ncreasingly evident that LC are unique in their development and
omeostasis compared to other DC subtypes. This will be the focus
f this review.
. Langerhans cell development
LC were discovered by Paul Langerhans in 1868 [17] and based
n the histological staining considered as of neuronal origin. It
ook another century before it became evident that LC belong to
he haematopoietic system and originate from bone marrow (BM)
recursors [18,19]. Finally, the pioneering work by Schuler and
teinman acknowledged LC as a non-lymphoid tissue contingent
f DC in skin [20]. LC have been regarded for long time as the
rchetype of a migratory DC that exhibit the classical text-book
C life cycle and thus frequently referred to as the Langerhans cell
aradigm [3,21]. This view has been revisited as it became clear
hat distinct DC populations emerge from independent develop-
ental branches and possesses non-overlapping immune functions
5,6,21].
.1. LC ontogeny
LC are unique in their development compared to other DC sub-
ets and are exceptionally long-lived cells [2]. LC are maintained
ocally in skin without the need of a BM-derived precursor due to
elf-renewal of LC or LC precursors in the epidermis [2,22,23]. Fur-
her studies suggest a local pool of proliferating haematopoietic
recursor cells that populate the skin during embryonic devel-
pment [24–26]. Therefore, it has been questioned whether or
ot under steady state conditions BM-resident LC precursors con-
ribute to LC homeostasis throughout life [22]. Recent studies
uggested the major contribution of a foetal liver-derived LC pre-
ursor with a myelo-monocytic phenotype similar to primitive yolk
ac (YS) macrophages [27]. Lineage-tracing experiments revealedelopmental Biology 41 (2015) 30–38 31
indeed contribution (∼10%) of YS progenitors to the pool of the
adult LC network [27,28]. The phenotype of these foetal LC precur-
sors is partially overlapping with the one described for MDP  in adult
BM showing expression of the Csf1 receptor and the chemokine
receptor CX3CR1. In contrast, MDP  are further characterized by
expression of Flt3 that is not required for LC development (see
Section 3.2.2) and MDP  have not formally proven to represent
a BM-derived precursor of LC. However, BM transplantation and
fate mapping experiments clearly demonstrated the presence of a
steady-state LC precursor in adult BM [18,19,23,29,30]. In addition,
we found the development of LC to be differentially regulated in
steady state and under inﬂammatory conditions. Our data demon-
strated the existence of two types of BM-derived LC, short-term and
long-term LC, that develop through different pathways in inﬂam-
mation and steady state, respectively [30]. These ﬁndings were
recently corroborated by further studies [31,32]. Long-term LC are
critically dependent on the transcription regulator Id2 (inhibitor of
DNA binding 2) during ontogeny and in steady state. Id2 is a TGF-1
target gene, pointing towards the critical role of TGF-1-signalling
for development and maintenance of steady-state LC (see Section
3.1) [33]. Since the identity of the steady-state LC precursor in adult
BM have so far not been precisely determined the exact mecha-
nisms that regulate LC development and homeostasis in the adult
remain elusive.
3. Receptor kinases in LC development
LC, like all mature blood cells, originate from a population
of multipotent haematopoietic stem cells (HSC), which due to
their sustained self-renewal capacity maintain haematopoiesis
throughout life (long-term HSC; Fig. 1). Lineage speciﬁcation and
development of mature blood cells involves the activation of
lineage speciﬁc genes and the selective repression of genes for alter-
native lineages, thereby leading to the establishment of a lineage
speciﬁc differentiation program. Numerous cytokines and growth
factors are known as essential mediators of lineage decisions [34].
Accordingly, various cytokines and growth factors have been iden-
tiﬁed to be vital for DC and/or LC development, such as Flt3-ligand
(Flt3L), GM-CSF, IL-34, and TGF-1 [6,7].
All haematopoietic factors are produced in local niches, which
provide a distinct cytokine/growth factor environment that con-
comitantly acts on all stem, progenitor and differentiated cell
populations present. Some cytokines will act in concert, partially
with overlapping functionalities, while other factors have a unique
function that eventually will lead to a speciﬁc and/or unidirectional
lineage commitment from the choice of several. Thus, it becomes
apparent that for a given cytokine milieu the susceptibility of
stem/progenitor and mature cells is to a large extent determined by
their expression of a speciﬁc repertoire of cytokine/growth factor
receptors. Given the importance of Flt3L for DC  development the
expression of its receptor Flt3 is prototypical: the differentiation
potential towards DC is maintained in all progenitors expressing
Flt3 (Fig. 1) and loss of Flt3 expression correlates with loss of DC
differentiation potential [35]. However, contrary to other DC sub-
sets LC develop independently of Flt3 and Flt3L (see Section 3.2.2)
[36,37].
Protein phosphorylation by the cytokine/growth factor recep-
tors upon ligand binding is one of the key events of the signal
transduction cascades that ﬁnally regulate cell fate determining
gene activities. Protein kinases (PKs) are among the largest families
of mammalian genes. The human kinome (the entire set of pro-genes of which 510 are orthologs of human protein kinases [38,39].
Kinases were classiﬁed into 9 groups comprising 134 families with
196 subfamilies (Fig. 2A) [38].
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Fig. 1. DC and LC development from haematopoietic stem and progenitor cells. Receptor kinase expression is depicted on LC, HSC and progenitor cells with DC differentiation
potential. Long-term reconstituting HSC (LT-HSC) maintain haematopoiesis throughout life due to their sustained self-renewal capacity and multilineage potential. LT-HSC
give  rise to multipotent progenitors (MPP) with diminished self-renewal potential that become increasingly restricted to speciﬁc lineage committed progenitors. Lymphoid-
primed multipotent progenitor (LMPP) lost erythro-megakaryocytic potential but can give rise to all other lineages. Macrophage-DC progenitors (MDP) give rise to monocytes,
macrophages, cDC, and pDC and are upstream of the DC-restricted common DC progenitors (CDP). MDP-derived Gr-1high/Ly-6C+ monocytes can further differentiate into
inﬂammatory DCs (MoDC) and short-term LC. The DC-potential is also retained in Flt3 expressing CLP. Whether MDP, CDP or CLP have the potential for long-term LC
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In the following sections we will focus on those cytokine/growth
actor receptors that possess an intrinsic catalytic kinase domain
nd for which a particular role in LC development has been
ddressed in vivo using speciﬁc gene-knockout mouse models
Table 1). This includes the serine–threonine receptor kinases TGF-
 receptor I and II and four RTKs (see Section 3.2). Fig. 2 shows
he phylogenetic relationship of these receptor kinases and their
omain organization.
.1. TGF-  ˇ receptorsMembers of the TGF- receptor family are divided into two
ubfamilies, the type I and type II receptors [38]. In mammalian
ells seven type I receptors have been identiﬁed and given a com-
on  nomenclature, i.e. activin-like kinase (ALK)1 to ALK7 (Fig. 2D).
able 1
henotype of receptor kinase-knockout mouse models on LC/DC development.
Mouse models lacking Langerhans cell cDC/
Receptor Ligand
TRI absent pres
TRII absent 
TGF-1 absent pres
BMP7 reduced 
Flt3 present redu
Flt3L present redu
Csf1R absent pres
M-CSF present redu
IL-34 absent pres
Met  present pres
Axl reduced evelopment in steady state and red arrows under inﬂammatory conditions. Solid
e references to colour in this ﬁgure legend, the reader is referred to the web version
Five type II receptors are known that are constitutively activated
through autophosphorylation of their cytoplasmic kinase domain
[40]. Ligand binding causes interaction between type I and type II
receptors, leading to phosphorylation of the type I receptors and
further activation of Smad-signalling pathways [40].
TGF- is the founding member of the TGF- superfamily, which
comprises more than 30 growth factors, including bone morpho-
genetic proteins (BMP) and activins [41]. TGF- is a covalently
linked homodimer and three isoforms exist, TGF-1, TGF-2 and
TGF-3. TGF- exclusively binds TGF- receptor II (TRII), which
then recruits and phosphorylates TGF--receptor I (TRI, ALK5).
ALK5 in turn phosphorylates Smad2 and Smad3. In some cell types,
TGF- has been shown to use ALK1-induced Smad1/5/8-signalling
as an alternative pathway, which is normally considered as the
BMP-induced pathway [40].
pDC Comment References
ent [52]
[51,53]
ent MDP/CDP present [50,51,53]
[55]
ced MDP/CDP present [9,36]
ced MDP reduced
NK cells reduced
[36,37]
ent [36]
ced Instructive on LT-HSC [59] [64,65,69]
ent Microglia reduced [63,67]
ent [85]
[73]
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Fig. 2. Receptor kinases involved in LC development. (A) Phylogenetic tree of the complete superfamily of 478 human protein kinases containing a eukaryotic protein kinase
(ePK)  catalytic domain. The similarity between the protein sequences of these catalytic domains is inversely related to the distance between their positions on the tree
diagram. Based on the sequence of their ePK domains, kinases are classiﬁed into seven major groups and other kinases, and are subdivided into families and colour-coded.
The  tyrosine kinases (TKs) Axl, Met, Csf1R, and Flt3 and the TGF- receptors 1 and 2 that have a speciﬁc role in LC development are indicated. AGC, containing PKA, PKG, PKC
families; CAMK Calcium/calmodulin-dependent protein kinase; CK1, Casein kinase 1; CMGC, containing CDK, MAPK, GSK3, CLK families; STE, homologs of yeast sterile kinases;
TKL,  tyrosine kinase-like. Modiﬁed from http://www.kinase.com/human/kinome/ according to [38]. (B) Dendrogram showing intrafamilial relationship of TKs involved in
LC  development. (C) Dendrogram showing intrafamilial relationship of serine–threonine receptor kinases (STRK) type I and type II including TGF- receptors involved in LC
development. Note that the distances to nodes in (B) and (C) are not in scale. (D) The domain structure of RTK and STRK families involved in LC development. The family
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TGF- is a pleiotropic protein, which plays a role in many biolog-
cal processes, including haematopoiesis and the immune system
42,43]. In general, TGF--signalling acts to maintain homeosta-
is by regulating processes like cell proliferation, differentiation
nd survival, however, the effect of TGF- is cell type, status and
ocation speciﬁc [41]. TGF- preserves quiescence of HSC [44] and
oss of TGF--signalling impairs their self-renewal capacity [45]. in this ﬁgure legend, the reader is referred to the web version of this article.)
Furthermore, TGF- differentially impacts on cell fate decisions and
differentiation. It promotes for example proliferation and differen-
tiation in myeloid-biased progenitors [46] but induces apoptosis
in lymphoid progenitors [47]. Additionally, TGF-1 induces DC
commitment in multipotent progenitors [48] and biases DC differ-
entiation towards cDC, by blocking pDC-speciﬁc gene expression
[49].
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TGF-1-signalling is an absolute prerequisite for LC homeostasis
n epidermis. TGF-1-deﬁcient mice lack LC [50] and TRI/ALK5-
nd TRII-deﬁcient mice show substantially reduced numbers of LC
51–53]. TGF-1-signalling is essential for retaining LC anchored in
heir epithelial environment in an immature and sessile state, while
evelopment and initial seeding of the epidermis occurs indepen-
ently of TGF-1-signalling. LC-speciﬁc elimination of TRI/ALK5,
RII or TGF-1 results in downregulation of E-cadherin [52,53]
hat mediates homophilic interactions of LC and keratinocytes
reviewed in [54]).
Importantly, it was recently shown that another TGF- family
ember, BMP7, modulates LC biology [55]. This BMP7/ALK3-
ignalling precedes TGF-1/ALK5-signalling during LC ontogeny
nd BMP7/ALK3-signalling therefore appears to impact on LC
ifferentiation instead of on LC maintenance. Accordingly, BMP7-
eﬁcient mice exhibit reduced numbers of LC [55].
.2. Receptor tyrosine kinases
Based on their domain structure all 58 mammalian RTKs fall
nto 20 distinct families [56]. So far, there are only clues on 4 RTKs
oncerning their role for LC development or maintenance, including
he Fms-like tyrosine kinase 3 receptor (Flt3, also known as Flk2
nd CD135), the colony-stimulating factor 1 receptor (Csf1R, also
amed fms, M-CSFR or CD115), the hepatocyte growth factor (HGF)
eceptor Met, and Axl. Flt3 and Csf1R belong to the same family of
lass III RTKs that includes Kit (the receptor for stem cell factor, SCF)
nd the platelet-derived growth factor receptors (PDGFR)  and ,
nd thus referred to as the PDGF receptor family (Fig. 2A and D).
.2.1. Csf1R
The receptor for Csf1/M-CSF is encoded by the fms  proto-
ncogene and its expression is restricted to the myeloid lineage,
ncluding progenitor cells, osteoclasts, and DC and to placental
rophoblasts during foetal development [57]. The fms  mRNA is
etectable in the earliest yolk sac phagocytes formed during mouse
evelopment, prior to many other monocyte/macrophage markers,
ncluding the transcription factor PU.1 [58]. In line with this ﬁnding
 recent report described that Csf1/M-CSF can directly induce PU.1
xpression and instruct myeloid cell-fate conversion in mouse HSC
59].
Interleukin-34 (IL-34) represents the second functional ligand
or Csf1R [60]. IL-34 shares no amino acid sequence homology
o Csf1/M-CSF but exhibits a similar three-dimensional topol-
gy. Functionally, IL-34 can compete with Csf1/M-CSF for CSF1R
inding, and can rescue the phenotype of Csf1/M-CSF-deﬁcient
Csf1op/op) mice [61]. However, IL-34 and Csf1/M-CSF differen-
ially bind to the extracellular domains of the receptor, which
auses subtle differences in signal activation and biological activ-
ties [61,62]. Moreover, the two cytokines display differential
patiotemporal expression patterns, suggesting nonredundant
oles in both developing and adult tissues [61–63].
The impact of Csf1R for DC development emerged just recently.
ost striking was the discovery of complete absence of LC in
dult Csf1R-deﬁcient mice [64], while normal numbers of LC were
resent in adult Csf1op/op mice [64,65]. Noteworthy, newborn
sf1op/op mice showed also reduced numbers of LC [64,66]. Due
o the fact that IL-34 had remained undiscovered as the second
sf1R-ligand for more than three decades the importance of the
sf1R has probably been underrated and the precise role of Csf1R
n DC development still remains to be explored. Highest expression
f murine IL-34 mRNA was found in brain and ear tissue (and very
ow expression in spleen) [61], while human IL-34 mRNA is most
bundantly expressed in spleen [60]. In line with the expression
roﬁle in mouse, IL-34-deﬁcient mice lack epidermal LC and have
educed number of microglia, the central nervous contingent ofelopmental Biology 41 (2015) 30–38
tissue macrophages [63,67]. In contrast, IL-34-deﬁcient mice
exhibit no defects in dermal DC and macrophages, monocytes, cDC
and pDC.
Expression of the Csf1-receptor was found in all progenitors
along the DC differentiation pathway, including MDP  and CDP
[8–13], and in multipotent progenitors including lymphoid-primed
multipotent progenitors and HSC [59,68]. The Csf1-receptor is also
expressed on lymphoid tissue pDC and cDC and in contrast to the
IL-34-knockout phenotype Csf1op/op mice revealed an approx-
imately two- and threefold reduction in splenic cDC  and pDC,
respectively [69]. In line with these results, both pDC and cDC can be
generated in vitro from BM cultures with M-CSF only [49,70]. Fur-
thermore, in vivo, pDC and cDC were increased in Flt3L-deﬁcient
mice treated with M-CSF, demonstrating that signalling via the
fms/Csf1-R alone can induce DC generation independent of Flt3L
[70].
3.2.2. Flt3
Flt3-ligand was identiﬁed as one of the key cytokines for DC
development as both cDC and pDC are generated from all Flt3+ DC
precursors (Fig. 1). Flt3 expression is found on short-term repopu-
lating multipotent progenitors but not on long-term HSC [71]. Flt3
is also expressed on further downstream linage-restricted progeni-
tors that retain DC-potential, including CLP and CMP  [35,72], MDP
[8–11], and CDP [11–13].
Flt3 expression is also maintained on pDC and cDC [35]. Accord-
ingly, overexpression or injection of recombinant Flt3L in mice or
humans leads to massive expansion of both pDC and cDC (reviewed
in [6]). In line with its in vivo impact on DC, Flt3L is readily used
to generate pDC and cDC from mouse BM or foetal liver cultures in
vitro. Moreover, Flt3L is also frequently used in in vitro culture for
generation of human LC derived from CD34+ HSC [33,55,73–76].
Based on the in vitro data it was  unexpected that the LC com-
partment is virtually unaffected in mice lacking either Flt3 or Flt3L
[36,37]. This is in stark contrast to the reduced numbers of pDC and
cDC found in Flt3- or Flt3L-deﬁcient mice [9,37]. Surprisingly, num-
bers of MDP  and CDP were also found reduced in Flt3L-deﬁcient
mice [37] but not in Flt3-deﬁcient mice [9,37]. Thus, Flt3 expression
is apparently not required for the development of DC progenitors
including MDP  and CDP but rather for maintenance of DC homeo-
stasis [9]. Such a concept would be in line with Flt3L ampliﬁes
Flt3-expressing DC precursors in vitro and in vivo, including LC pro-
genitors but maintenance of DC/LC is dependent on different locally
provided cytokines within the various lymphoid and nonlymphoid
tissues.
3.2.3. Met
Met  was originally identiﬁed as an oncogene and later found
to represent the receptor for HGF, also known as scatter factor
[77,78]. Met  is a member of the HGF receptor subfamily of RTKs
that includes the highly homologous kinase Ron (Fig. 2). Ron is the
receptor for the macrophage stimulating protein (MSP), which is
structurally related to HGF. Met  and Ron share a distinct domain
structure as disulphide-linked / heterodimers formed from a
single-chain precursor by proteolytic cleavage. The transmem-
brane -chain subunit contains the intracellular tyrosine kinase
domain and extracellularly a so-called ‘sema’ domain that has
structural analogies with the extracellular domains of semaphorins
and plexins (Fig. 2). Met-signalling after HGF binding confers mito-
genic, morphogenic, and motogenic activity to various cells and is
essential during embryonic development, as shown by the lethal
phenotype in utero of conventional Met- or HGF-null mutations
[77,78].
Met  expression in the haematopoietic compartment was found
in stem and progenitor cells including long-term HSC [79,80], B
cells [81,82], and monocytes [83]. Met  expression was also found
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n all DC subtypes so far analyzed including splenic cDC and pDC
84,85], dermal DC, LC and DC derived from BM cultures [85,86].
et  expression is further upregulated with maturation of DC [85].
hether it is functionally expressed on DC-progenitors such as
DP or CDP has so far not been addressed.
Recently, it became evident that Met-signalling is critically
nvolved in the emigration of LC and dDC from skin. Stimulation
ith HGF alone is sufﬁcient to induce LC emigration from skin,
hile it did not serve as a chemoattractant for DC [85,86]. HGF stim-
lation enhances adhesion of DC to laminin, suggesting a functional
nterplay with integrins like in other cellular systems [86,87]. Inter-
stingly, the 6 integrin, part of the laminin receptor 64 integrin,
as found to be required for LC emigration from epidermis [88].
y using a conditional Met-deﬁcient mouse model (Metﬂox/ﬂox),
e further demonstrated that Met-signalling in skin-resident LC
nd dDC is essential for their detachment and emigration from
urrounding tissue upon inﬂammation. As a consequence, Met-
eﬁcient LC and dDC failed to reach draining LNs and thus lacked
he capacity to mount an immune response in contact hypersen-
itivity reactions [85]. Additionally, Met-signalling in DC regulates
atrix metalloproteinase (MMP)-2 and MMP-9 activity required
or LC transmigration through extracellular matrix [85,89,90]. In
ontrast, Met-signalling was not required for stem cell homing into
he BM and subsequent development and integration of LC into
pidermis [85].
.2.4. Axl
The RTK Axl (also known as Ark, Ufo, and Tyro7) is the founding
ember of the TAM family of RTKs, which also includes Tyro3 and
er  (Fig. 2) [91,92]. TAM receptors have identical structures and
re activated by dimerization. The predominant ligand for Axl is the
rotein encoded by growth-arrest-speciﬁc gene 6 (GAS6), which is
hared by its family members Tyro3 and Mer. Tyro3 is additionally
ctivated by protein S, a factor with an additional function as an
nticoagulant in blood. In cells co-expressing Mer  and Tyro3, pro-
ein S is also a potent Mer  agonist [91]. Hence, it is suggested that
AM receptors can form heterodimers among each other, but the
echanism and functional consequences of hetero- versus homo-
imerization remain still elusive [91].
Axl, Mer  and Tyro3 are most closely related to Met and Ron
Fig. 2B) [38,91]. A crosstalk of Axl with Met-signalling is suggested
o play a role in cellular migration and survival [93,94]. In line
ith this, expression of Axl in tumours correlates with invasion
nd metastatic cell migration [92].
In the haematopoietic compartment, Axl is expressed in DC and
acrophages but not in monocytes, granulocytes, or lymphocytes
nd was found to be important for the homeostasis of the immune
ystem. Axl is strongly induced in DC and macrophages by type I
nterferons upon Toll-like receptor (TLR) stimulation during inﬂam-
ation [95,96]. TAM-signalling promotes uptake of apoptotic cells
y phagocytes and negatively regulate innate immune responses
y limiting pro-inﬂammatory TLR activation during inﬂammation
95–97]. Loss of Axl together with its family members has severe
mmunological consequences. TAM-triple knockout mice display
onstitutively activated DC, macrophages, T and B cells and develop
 broad-spectrum of autoimmune disorders [91].
In steady state Axl plays a role in the homeostasis of skin
mmunity by maintaining the LC network in the epidermis [73].
xl expression is rapidly induced during early LC differentiation
nd remains as a key downstream effector of TGF-1-signalling.
C in skin are constantly exposed to GAS6 that is abundantly
xpressed in keratinocytes. As a result, uptake of apoptotic mate-
ial is enhanced and TLR-mediated LC maturation is impeded.
onsequently, down regulation of endogenous Axl-signalling
s an essential step for LC maturation and emigration from
kin [73].elopmental Biology 41 (2015) 30–38 35
4. EMT  and MET  in the LC life cycle
LC development and immunological function are closely inter-
related to mobility. LC precursors leave their cradle (whether yolk
sac, foetal liver, or bone marrow) to immigrate into the epidermis.
LC become sessile and embedded within the tissue via adherens and
tight junctions, and maintain homeostasis in situ by self-renewal.
This stationary phenotype is abandoned only when LC become acti-
vated and start to emigrate from the epidermis to skin draining
LNs.
A similar spatial and temporal sequence of cellular activi-
ties is referred to as ‘invasive growth’ and includes disruption
of cell-to-cell contacts, mobilization from the primary tissue of
residence, prevention of apoptosis, interstitial migration, crossing
tissue boundaries, homing to secondary target tissue and prolif-
eration [87,98]. The aberrant execution of this sequence is well
known in tumour progression towards metastasis. Moreover, this
sequence of events has a physiological relevance during embry-
onic development. In the adult it is reactivated in wound healing
and tissue regeneration. The conversion of an immobile epithe-
lial (or in some cases endothelial) cell to a motile and migratory
phenotype is called epithelial-to-mesenchymal transition (EMT).
This genetically driven program is transient and migratory cells
at their secondary site of residence reconvert by mesenchymal-
to-epithelial transition (MET) back into a stationary phenotype
[99–101].
One of the molecular hallmarks of EMT is the loss of E-
cadherin expression. EMT  is characterized by downregulation of
further components that build up adherens and tight junction com-
plexes, including EpCAM, occludins, claudins, zonula occludens
(ZO) proteins, and cytokeratins and thereby decomposes cell-to-
cell contacts. Simultaneously, cells acquire mesenchymal features,
such as expression of N-cadherin, vimentin, integrins, and matrix-
metalloproteinases (MMP)  and reorganization of the cytoskeleton,
which altogether facilitate cell migration. The EMT  and MET pro-
grams are controlled by an intricate network of transcriptional
regulators belonging to three families: the zinc ﬁnger factors Snail
and Slug, the zinc ﬁnger and E-box binding proteins (ZEB) 1 and
2, and basic helix-loop-helix factors (e.g. Twist1) (reviewed in
[98,99,101]).
Both signalling by TGF- receptor and Met  have long been
known to play important roles in invasive events during embry-
onic development, tissue regeneration, and cancer progression.
Yet, there are open questions. TGF--signalling is involved in con-
trolling both EMT  and MET  transitions. TGF- is often found as
a potent EMT  inducer, while several BMPs, including BMP7, can
promote MET  [100,101]. It is nowadays reasoned that changes in
components of the TGF- signal-transduction machinery account
for divergent cellular responses [41]. One example is the differen-
tial activation of ALK1 and ALK5 in endothelial cells. TGF--induced
ALK1-signalling leads to Smad1 and Smad5 phosphorylation result-
ing in cell proliferation and migration, while ALK5-signalling
activates Smad2 and Smad3 leading to inhibition of both prolif-
eration and migration [102].
In LC development, TGF--signalling is essential to main-
tain the stationary, more epithelial-like phenotype rather than
inducing EMT  (Fig. 3). LC in skin express E-cadherin and vari-
ous other epithelial-like junctional proteins, including claudin-1,
EpCAM/TROP1, TROP2, ZO-1, occludin, JAM1, and cytokeratins,
which allows them to functionally integrate into the keratinocyte
layer [50,74,76,103,104]. By employing conditional gene-knockout
mice recent studies showed that TGF--signalling retains LC in
the epidermis by inhibiting their migration and maintaining their
epithelial phenotype. Deletion of either TGF-1 or its receptors
TRII and TRI/ALK5 in LC causes them to acquire a migratory
phenotype. In particular, adhesion appears to be reduced through
36 T. Hieronymus et al. / Seminars in Cell & Dev
Fig. 3. EMT  and MET  in the LC life cycle. LC/LC precursors undergo MET  in epidermis.
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bone marrow progenitor speciﬁc for macrophages and dendritic cells. ScienceGF-/BMP-signalling is essential to keep the stationary, epithelial-like phenotype.
et-signalling is an inducer of EMT  critically involved in LC emigration upon acti-
ation.
he downregulation of E-cadherin and EpCAM, while the expres-
ion of maturation markers was upregulated [52,53]. Interestingly,
obr et al. [53] showed that inﬂammatory activation of steady-
tate LC, which induced their emigration from epidermis, disrupts
GF-1-mediated pSmad2/3-signalling.
Recent studies by the Strobl lab further corroborated the
ole of TGF-- and BMP7-signalling in controlling EM-  and ME-
ransitions in LC development [55,75,76]. They found that BMP7
s highly expressed in the basal and suprabasal layers of the epi-
ermis where LC reside in steady state. BMP7 was able to induce
C differentiation in a human culture model via ALK3 in the
bsence of canonical TGF--ALK5-signalling, while TGF-1 acti-
ated both ALK3 and ALK5 pathways. In BMP7-deﬁcient mice LC
umbers were signiﬁcantly diminished [55] in line with the role
f BMP7 in MET. Furthermore, TGF--signalling induced a num-
er of epithelial adhesion molecules in LC during differentiation
ncluding E-cadherin [76]. Activation of LC was found to induce
xpression of the EMT  regulators ZEB1 and ZEB2 and downreg-
lation of E-cadherin accompanied by upregulated expression of
-cadherin, a marker of a mesenchymal phenotype [75]. In con-
rast, mesenchymal cytoskeletal markers such as vimentin and
mooth-muscle-actin were not found to be regulated [75], which
s in line with previous observed expression of vimentin in LC of
ouse epidermis [105].
Taken together, the concept emerges that in long-term LC devel-
pment cells execute a MET-like program, while short-term LC are
nable to accomplish the full transition from their mesenchymal
o an epithelial phenotype. MET  during LC development appears to
e tightly regulated by expression of and signalling via a speciﬁc
ombination of TGF- receptors. Consequently, alteration or lack
f one of these pathways will result in incomplete MET. Indeed, the
xpression of TGF-1 target genes in short-term LC was  found to
e lower than in long-term LC [30]. It is tempting to speculate that
LK5-associated Smad 2/3-signalling pathways are inefﬁciently
ctivated in short-term LC. Yet, whether genetically driven EMT
nd MET  programs are in fact differentially executed in long-term
ersus short-term LC remains to be addressed.
Signalling by Met  is a potent inducer of EMT. Met-signalling in
C appears to recapitulate properties of EMT  (Fig. 3). Met-signalling
egulates MMP  activities in DC [85], which is a characteristic feature
f a mesenchymal and migratory phenotype upon EMT  induction.
his is similar in tumour cells where Met-signalling can stimulate
he proteolytic activity of MMPs, thus facilitating their dissocia-
ion and invasive scattering. Strikingly, the importance of MMPs,elopmental Biology 41 (2015) 30–38
particularly MMP-2 and MMP-9, in LC migration has been well
established [89,90].
However, it remains unclear how Met-signalling in LC induces
EMT  by exploiting downstream signalling pathways that are com-
monly shared by other RTKs. Where does the speciﬁcity for
inducing LC emigration from the epidermis come from? Coop-
eration with other cell surface receptors important in regulating
cellular migration, such as 64 integrin, plexin-B1, CD44, Axl, and
Mif  receptor have been considered to act in concert in a context
and tissue environment-dependent fashion [82,87,94,98]. For some
of these factors expression in LC has been already demonstrated.
However, whether or not interaction with Met  takes place in LC
and the precise mechanisms of downstream signalling pathways
remain to be addressed.
5. Conclusions
Cytokine/growth factor receptor kinases, including TGF--
receptors and Csf1R, Met, and Axl RTKs are critically involved in LC
homeostasis. Receptor kinase-signalling has a signiﬁcant impact on
the activation of lineage speciﬁc genes and the selective repression
of genes for alternative lineages, thereby leading to the establish-
ment of a LC speciﬁc differentiation program. Apparently, the entire
set of cell surface receptors allows congregating all extrinsic cues
from the local niches that impact on LC fate. Compared to the
dimension of the mammalian kinome there is yet rather limited
data about the signal transduction pathways critically involved in
LC and DC development. This needs clearly more profound investi-
gations.
The recent ﬁndings reviewed here emphasises the role of adhe-
sion and migration for LC homeostasis and the control of these
mechanisms by TGF-- and Met-signalling pathways (Fig. 3). These
pathways drive speciﬁc cell fate transition programs known as EMT
and MET. However, mechanisms controlling cell motility might be
different in mesenchymal cells and DC. Thus, further studies are
needed (i) to corroborate the concept that EMT  and MET  programs
are involved in LC development and (ii) whether or not this concept
is also operating in other DC subsets, such as interstitial DC in gut,
lung or other peripheral tissues.
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